Cancer Research Meeting Calendar  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 8762, September 15, 2007. doi: 10.1158/0008-5472.CAN-06-4807
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rassool, F. V.
Right arrow Articles by Padua, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rassool, F. V.
Right arrow Articles by Padua, R. A.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia?

Feyruz V. Rassool1, Terry J. Gaymes2, Nader Omidvar3, Nicola Brady2, Stephanie Beurlet4, Marika Pla4, Murielle Reboul4, Nicholas Lea2, Christine Chomienne4, Nicholas S.B. Thomas2, Ghulam J. Mufti2 and Rose Ann Padua4

1 Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland; 2 King's College London, Department of Haematological Medicine, Leukemia Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill Campus, London, United Kingdom; 3 School of Biosciences, Cardiff University, Cardiff, United Kingdom; and 4 INSERM U718, Institût Universitaire d'Hématologie, IFR 105, Hôpital Saint-Louis, Paris, France

Requests for reprints: Feyruz Rassool, University of Maryland School of Medicine, Department of Radiation Oncology, 655 West Baltimore Street, BRB 7-009, Baltimore, MD 21201-1509. Phone: 410-706-5337; Fax: 410-706-3000; E-mail: frassool{at}som.umaryland.edu or Rose Ann Padua, Institut National de la Sante et de la Recherche Medicale (INSERM) U718, Institût Universitaire d'Hématologie, Hôpital Saint Louis, 75010 Paris, France. Phone: 33-1-53-72-40-18; Fax: 33-1-53-72-40-16.

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of disorders characterized by ineffective hematopoiesis, with an increased propensity to develop acute myelogenous leukemia (AML). The molecular basis for MDS progression is unknown, but a key element in MDS disease progression is loss of chromosomal material (genomic instability). Using our two-step mouse model for myeloid leukemic disease progression involving overexpression of human mutant NRAS and BCL2 genes, we show that there is a stepwise increase in the frequency of DNA damage leading to an increased frequency of error-prone repair of double-strand breaks (DSB) by nonhomologous end-joining. There is a concomitant increase in reactive oxygen species (ROS) in these transgenic mice with disease progression. Importantly, RAC1, an essential component of the ROS-producing NADPH oxidase, is downstream of RAS, and we show that ROS production in NRAS/BCL2 mice is in part dependent on RAC1 activity. DNA damage and error-prone repair can be decreased or reversed in vivo by N-acetyl cysteine antioxidant treatment. Our data link gene abnormalities to constitutive DNA damage and increased DSB repair errors in vivo and provide a mechanism for an increase in the error rate of DNA repair with MDS disease progression. These data suggest treatment strategies that target RAS/RAC pathways and ROS production in human MDS/AML. [Cancer Res 2007;67(18):8762–71]




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. Cavelier, C. Didier, N. Prade, V. Mansat-De Mas, S. Manenti, C. Recher, C. Demur, and B. Ducommun
Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
Cancer Res., November 15, 2009; 69(22): 8652 - 8661.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Chen, N. Mitsutake, K. LaPerle, N. Akeno, P. Zanzonico, V. A. Longo, S. Mitsutake, E. T. Kimura, H. Geiger, E. Santos, et al.
Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene
PNAS, May 12, 2009; 106(19): 7979 - 7984.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. Fontenay and E. Gyan
Apoptotic pathways to death in myelodysplastic syndromes
Haematologica, September 1, 2008; 93(9): 1288 - 1292.
[Full Text] [PDF]


Home page
Cancer Res.Home page
H. Kadara, E. Tahara, H.-J. Kim, D. Lotan, J. Myers, and R. Lotan
Involvement of Rac in Fenretinide-Induced Apoptosis
Cancer Res., June 1, 2008; 68(11): 4416 - 4423.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Sallmyr, J. Fan, K. Datta, K.-T. Kim, D. Grosu, P. Shapiro, D. Small, and F. Rassool
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML
Blood, March 15, 2008; 111(6): 3173 - 3182.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.